Comparative Pharmacology
Head-to-head clinical analysis: DRIZALMA SPRINKLE versus FETZIMA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRIZALMA SPRINKLE versus FETZIMA.
DRIZALMA SPRINKLE vs FETZIMA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibition, resulting in increased synaptic serotonin concentrations and enhanced serotonergic neurotransmission.
Fetzima (levomilnacipran) is a selective serotonin and norepinephrine reuptake inhibitor (SNRI). It inhibits the reuptake of serotonin and norepinephrine, with approximately 2-fold higher potency for norepinephrine reuptake inhibition, which enhances neurotransmission in the central nervous system.
60 mg orally once daily, with or without food. Capsules may be swallowed whole or opened and sprinkled onto applesauce.
20 mg orally once daily for 2 days, then 40 mg once daily for 2 days, then 80 mg once daily for 2 days, then 120 mg once daily; maximum dose 120 mg/day.
None Documented
None Documented
12-15 hours; steady-state achieved in 2-3 days; no significant accumulation with q12h dosing.
Terminal elimination half-life is approximately 12 hours for levomilnacipran; at steady state, half-life supports once-daily dosing without extensive accumulation.
Primarily renal (approx. 70% as unchanged drug and metabolites); 30% fecal/biliary.
Primarily renal (approximately 65% as unchanged levomilnacipran and 25% as N-desmethyllevomilnacipran); fecal excretion accounts for ~8%.
Category C
Category C
SNRI Antidepressant
SNRI Antidepressant